At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure
In Brief
A Phase 2 clinical trial evaluating Placebo and ISIS 757456 for Mild Hypertension. Completed, enrolled 25 participants across 6 sites.
Detailed Summary
This was a Phase 2, double-blind, randomized, placebo-controlled study of IONIS-AGT-LRx conducted in mild hypertensive participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartJan 2019
Primary CompletionNov 2019
TodayJul 2026
First PostedOct 22, 2018
Enrollment StartJan 3, 2019
Primary CompletionNov 13, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.7 years ago
Interventions
Placebodrug
Placebo matching solution administered as SC injection.
ISIS 757456drug
Administered as SC injection.